We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02279433
Recruitment Status : Completed
First Posted : October 31, 2014
Last Update Posted : September 22, 2020
Information provided by (Responsible Party):
AnHeart Therapeutics Inc.

Brief Summary:
DS-6051b is an orally administered inhibitor of the tyrosine kinases (ROS1) and neurotropic tyrosine kinase receptors (NTRK). This phase 1 first-in-human study evaluates safety and tolerability of DS-6051b in cancer subjects and identify a recommended phase 2 dose (RP2D). In addition, this study will also assess the pharmacokinetic (PK)/pharmacodynamic (PD) profiles and preliminary efficacy of DS-6051b.

Condition or disease Intervention/treatment Phase
Solid Tumors Drug: DS6051b Phase 1

Detailed Description:

The Dose Escalation part (Part 1) of this study will evaluate safety and tolerability, and determine the tentative RP2D. Plasma exposure of DS-6051a and the exposure - QT interval prolongation relationship will also be assessed. Approximately 30 subjects with advanced solid tumors harboring ROS1 or NTRK1, NTRK2, or NTRK3 rearrangement, neuroendocrine carcinoma, or with advanced solid tumors and tumor-induced pain will be enrolled.

The Food Effect (FE) part of this study is to determine the effect of food on the PK of DS-6051a following administration of a single oral dose of DS-6051b. The safety and tolerability of DS-6051b administered with or without food will also be assessed.

After the safety profile of DS-6051b is adequately evaluated, the Dose Expansion part (Part 2) will be initiated to further assess the safety and tolerability, and preliminarily evaluate the efficacy of DS-6051b at the tentative RP2D. Approximately 40 cancer subjects carrying a ROS1 or NTRK1, NTRK2, or NTRK3 rearrangement will be enrolled.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 46 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/1B Multi-Center, Non Randomized, Open-Label, Multiple Dose First-In-Human Study Of DS-6051b, An Oral ROS1 And NTRK Inhibitor, In Subjects With Metastatic and/or Unresectable Solid Tumors
Study Start Date : September 2014
Actual Primary Completion Date : March 2019
Actual Study Completion Date : March 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: DS-6051b
DS-6051b is orally administered as 50 mg and 200 mg capsules once daily on Days 1 to 21 of a 21-day cycle. Dose escalation in Part 1 will continue until tentative Recommended Part 2 Dose (RP2D) is determined. In Part 2 participants will receive the RP2D.
Drug: DS6051b
DS-6051b 50 mg and 200 mg capsules for oral administration
Other Names:
  • Investigational product
  • DS-6051a (a free base of 6051b)

Primary Outcome Measures :
  1. Part 1: Number of participants with dose-limiting toxicities [ Time Frame: within 21 days following the first dose of treatment ]
  2. Tumor response [ Time Frame: up to 2 years ]
    Tumor response will be assessed using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1.

Secondary Outcome Measures :
  1. Maximum concentration (Cmax) for DS-6051a [ Time Frame: At Days 1 and 15 of Cycle 1 (21 days) ]
  2. Time to maximum concentration (Tmax) for DS-6051a [ Time Frame: At Days 1 and 15 of Cycle 1 (21 days) ]
  3. Area under the concentration-time curve from time zero to t (AUC0-t) for DS-6051a [ Time Frame: At Days 1 and 15 of Cycle 1 (21 days) ]
  4. Change from baseline in QTc interval [ Time Frame: within 2 years ]
    ECGs performed to assess QTc interval (ms) at baseline and on study treatment and at the end of treatment visit.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Histologically or cytologically confirmed diagnosis of advanced solid tumors that have relapsed from or are refractory to standard treatment or for which no standard treatment is available
  2. Part 1 Dose Escalation subjects must meet 1 of the following criteria:

    • Solid tumors with documented ROS1, NTRK1, NTRK2, or NTRK3 rearrangement
    • Neuroendocrine tumors
    • Solid tumors with tumor-induced pain
  3. Part 2 Dose Expansion subjects must meet 1 of the following criteria:

    • NSCLC with documented ROS1, NTRK1, NTRK2, or NTRK3 rearrangement
    • k-RAS wild-type CRC with documented NTRK1, NTRK2, or NTRK3 rearrangement
    • Other solid tumors with documented ROS1, NTRK1, NTRK2, or NTRK3 rearrangement
    • Pulmonary LCNEC;
  4. Male or female ≥18 years of age
  5. Eastern Cooperative Oncology Group performance status 0 to 1
  6. Adequate organ function
  7. Adequate blood clotting function
  8. Women of childbearing potential must have a negative pregnancy test
  9. Willingness to provide archival tumor samples
  10. Other inclusion criteria may apply

Exclusion Criteria:

  1. Hematological malignancies
  2. Known positive HIV infection, or active hepatitis B or C infection
  3. Comorbidity that would interfere with therapy
  4. Receipt of an allogeneic bone marrow or allogeneic stem cell transplant
  5. Concomitant medical condition that would increase the risk of toxicity, in the opinion of the Investigator or Sponsor
  6. History of myocardial infarction and unstable angina within 6 months before study drug treatment; symptomatic congestive heart failure (Congestive Heart Failure New York Heart Association Class III or IV); congenital long QT syndrome; or ventricular arrhythmias defined as grade ≥2 according to NCI CTCAE, v4
  7. Clinically active primary central nervous system tumors or brain metastases with the exception of subjects with glioblastoma multiform that carry ROS1 rearrangement
  8. Unresolved toxicities from previous anticancer therapy
  9. Systemic treatment with anticancer therapy within 3 weeks before study drug treatment
  10. Therapeutic radiation therapy or major surgery within 4 weeks before study drug treatment or palliative radiation therapy within 2 weeks before study drug treatment
  11. Participation in a therapeutic clinical study within 3 weeks for biological treatments, and within 2 weeks or 5 half-lives, whichever is longer, for small molecule agents, before study drug treatment
  12. Concomitant treatment with strong inhibitors or inducers of CYP3A4 and P-glycoprotein
  13. Clinically significant malabsorption syndrome or other gastrointestinal disease that would impact drug absorption
  14. QTcF values higher than 450 ms at screening
  15. Breastfeeding
  16. Other exclusion criteria may apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02279433

Layout table for location information
United States, Arizona
HonorHealth Research Institute
Scottsdale, Arizona, United States, 85258
United States, California
Chao Family Comprehensive Cancer Center of
Orange, California, United States, 92868
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Dana Farber Cancer Inst.
Boston, Massachusetts, United States, 02215
United States, New York
New York University
New York, New York, United States, 10016
United States, Texas
South Texas Accelerated Research Therapeutics
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
AnHeart Therapeutics Inc.
Layout table for investigator information
Study Director: Study Director Oncology AnHeart Therapeutics Inc.
Layout table for additonal information
Responsible Party: AnHeart Therapeutics Inc.
ClinicalTrials.gov Identifier: NCT02279433    
Other Study ID Numbers: DS6051-A-U101
First Posted: October 31, 2014    Key Record Dates
Last Update Posted: September 22, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by AnHeart Therapeutics Inc.:
Lung Neoplasms
Colorectal Neoplasms
Neuroendocrine Tumors
Pancreatic Neoplasms